Fixed-Dose Telmisartan/Hydrochlorothiazide in Comparison With Losartan/Hydrochlorothiazide in Decreasing Serum Hepatocyte Growth Factor and Improving Endothelial Dysfunction in Hypertensive Patients
Fixed-Dose Telmisartan/Hydrochlorothiazide in Comparison With Losartan/Hydrochlorothiazide in Decreasing Serum Hepatocyte Growth Factor and Improving Endothelial Dysfunction in Hypertensive Patients
复制标题
固定剂量替米沙坦/氢氯噻嗪与氯沙坦/氢氯噻嗪降低高血压患者血清肝细胞生长因子和改善内皮功能障碍的比较
DOI：
10.1536/ihj.51.252
复制
发表时间：
2010-07-01
影响因子：
1.5
通讯作者：
Wang, Yuan
中科院分区：
文献类型：
--
作者：
Hu, Ze-Ping;Wang, Bang-Ning;Wang, Yuan
提倡采用血管紧张素 II 受体阻滞剂和氢氯噻嗪 (HCT) 联合治疗来控制高血压 (HT)。肝细胞生长因子（HGF）可能是评估内皮功能障碍（ED）的新标志物，而内皮功能障碍是治疗HT的潜在靶点。本研究的目的是比较替米沙坦/HCT与氯沙坦/HCT对高血压患者血清HGF和ED的影响。高血压患者被随机分为替米沙坦/HCT组（T组）或氯沙坦/HCT组（L组），每天服用任一药物一粒，持续8周。治疗前和治疗8周后测定血清HGF、一氧化氮（NO）、血浆血管性血友病因子（vWF）和内皮素（ET）。选取20名健康受试者作为对照（对照组）。高血压患者HGF、vWF、ET、ET/NO比值高于对照组，NO低于对照组（均P < 0.01）。治疗8周后，两组HGF、vWF、ET均下降，NO均显着升高（均P < 0.01）。两组间BP、HGF的降低和NO（Delta NO）的增加均无显着性差异（均P > 0.05），但vWF和ET（Delta ET）的降低以及Delta ET/Delta NO比值T组的降低较L组更明显（均P < 0.01）。两组中大部分测量参数的变化与血压降低程度均无显着相关性。替米沙坦/HCT和氯沙坦/HCT均可降低血清HGF并改善ED，且与降压作用无关。然而，当降压效果相同时，替米沙坦/HCT 对 ED 的改善可能优于氯沙坦/HCT。 （国际心脏杂志 2010；51：252-258）
Combined treatment with an angiotensin II receptor blocker and hydrochlorothiazide (HCT) is advocated to control hypertension (HT). Hepatocyte growth factor (HGF) may be a new marker to evaluate endothelial dysfunction (ED), which is a potential target in treating HT. The aim of the present study was to compare the effects of Telmisartan/HCT with Losartan/HCT on serum HGF and ED in hypertensive patients.Hypertensive patients were randomly divided into a Telmisartan/HCT (group T) or Losartan/HCT group (group L) and received one tablet of either drug per day for 8 weeks. Serum HGF, nitric oxide (NO), plasma von Willebrand factor (vWF), and endothelin (ET) were measured before treatment and after 8 weeks of treatment. Twenty healthy subjects were selected as controls (control group).HGF, vWF, ET, and the ET/NO ratio were higher, and NO was lower in hypertensive patients than those in the control group (all P < 0.01). After treatment for 8 weeks, HGF, vWF and ET decreased, and NO increased significantly in both groups (all P < 0.01). The reductions in BP and HGF and increase in NO (Delta NO) were not significantly different between the two groups (all P > 0.05), but the reductions in vWF and ET (Delta ET) and Delta ET/Delta NO ratio were more obvious in group T than in group L (all P < 0.01). There was no significant correlation between the changes in most of the measured parameters and the extent of BP reduction in either group.Both Telmisartan/HCT and Losartan/HCT could decrease serum HGF and improve ED, which was independent of the antihypertensive effects. However, the improvement in ED may be superior with Telmisartan/HCT than Losartan/HCT when the BP-lowering effects are the same. (Int Heart J 2010; 51: 252-258)